


1 Scheme of study

Previously untreated frail and unfit patients with MM ineligible for high dose therapy and peripheral stem cell transplantation



* in case either ixazomib or daratumumab is delayed or withhold dexamethasone should be administered , either i.v. or p.o.

** in case daratum umab is delayed or withhold dexamethasone is NOT administered .

Post-daratumumab infusion medication , consisting of 4 mg of dexamethasone will be routinely administered in the first 4 cycles, not during subsequent cycles , provided there were no IRRs during previous cycles . In case of infusion related reactions in the first 2 cycles dexamethasone dose should maintained at 20 mg and additional measures described in paragraph J 2 should be taken. In case of infusion related reactions during lowering the dose to 10 mg of dexamethasone or lowering the dose because of side effects to 4 mg of dexamethasone increase to the previous dose level .